Gregory A. Lazar,Sher Bahadur Karki,Gregory L. Moore
申请号：
US13747317
公开号：
US09475881B2
申请日:
2013.01.22
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
